Adenomatous polyposis coli protein 2 (APC2)

Adenomatous polyposis coli protein 2 (APC2) is a cytoplasmic protein homologous to the canonical tumor suppressor APC, and acts as a regulatory component of the Wnt signaling pathway. APC2 is evolutionarily conserved from Drosophila to humans and can interact with key Wnt pathway components, including β-catenin, forming parts of the β-catenin destruction complex, though it is less efficient than APC in this role[1][2][4]. Loss or mutation of APC2 subtly increases Wnt pathway activity by impairing β-catenin degradation, particularly in tissues such as the intestinal crypt, where it modifies stem cell dynamics and apoptosis without causing wholesale disruption of tissue architecture[1]. APC2 does not appear to be a frequent site of cancer-causing mutations in humans, but its deficiency may contribute to altered stem cell fitness and tissue homeostasis. Unlike the related APC protein, APC2 is not a current therapeutic target; there are no known drugs that specifically target or modulate APC2 function, and its principle biomedical significance lies in its role in fundamental Wnt pathway regulation and possibly as a modifier in cancer when APC is lost or mutated[1][2][4]. Note: While APC2 is critical in Wnt biology, it is not generally considered a *therapeutic target* and no small molecule or biologic agents act directly upon it. For research or clinical purposes, interest in APC2 centers around its basic biological function rather than its druggability.

Other names

APC2APCLAPC-likeAPC-like proteinadenomatous polyposis coli likeadenomatous polyposis coli protein-likeadenomatosis polyposis coli 2MRT74

Not drugged; acts physiologically by forming β-catenin destruction complexes in Wnt pathway